Brockmöller J,Tzvetkov MV .2008 .Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol, 64(2) : 133-57.
Lam RW .2018 .. Depression, : .
Hayashi M,Hamdy DA,Mahmoud SH .2022 .Applications for pharmacogenomics in pharmacy practice: a scoping review. Res Soc Adm Pharm, 18(7) : 3094-118.
Saunders H,Harris D,Chirilă RM .2020 .Pharmacogenomics: introduction and use in clinical practice. Rom J Intern Med, 58(2) : 69-74.
Mrazek DA,Hornberger JC,Altar CA,Degtiar I. .2014 .A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. , 65(8) : 977-87.
Manchia M,Pisanu C,Squassina A,Carpiniello B .2020 .Challenges and future prospects of precision medicine in psychiatry. Pharmacogenomics Pers Med, 13 : 127-40.
Risch N,Herrell R,Lehner T,Liang KY,Eaves L,Hoh J .2009 .Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. Jama, 301(23) : 2462-71.
Turpeinen M,Zanger UM .2012 .Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact, 27(4) : 185-97.
Magalhães PR . .Pharmacometric evaluation of the clinical impact of genetic polymorphisms of the cytochrome P450 and P-Glycoprotein in the Pharmacokinetics and Pharmacodynamics of Antidepressant Drugs: Fluoxetine, Paroxetine and Venlafaxine [dissertation]. , 00500 : .
Shields MR . .. , : .
Allen JD,Pittenger AL,Bishop JR .2022 .A scoping review of attitudes and experiences with pharmacogenomic testing among patients and the general public: implications for patient counseling. J Pers Med, 12(3) : 425.
Waldman L,Shuman C,Cohn I,Kaiser A,Chitayat D,Wasim S .2019 .Perplexed by PGx? Exploring the impact of pharmacogenomic results on medical management, disclosures and patient behavior. Pharmacogenomics, 20(5) : 319-29.
Bryant B . .Apprenticeship to degree: the co-evolution of twentiethcentury pharmacy practice and education from a Queensland and regional perspective [dissertation]. Rockhampton (AU): CQUniversity.. , : .
Balogun OD,Ayo-Farai O,Ogundairo O,Maduka CP,Okongwu CC,Babarinde AO .2024 .The role of pharmacists in personalised medicine: a review of integrating pharmacogenomics into clinical practice. Int Med Sci Res J, 4(1) : 19-36.
Bishop JR,Schneiderhan ME,Butler T,Carpentier RM,Heins KR,Formea CM .2024 .Pharmacogenomics to support mental health medication therapy management: Clinical practice considerations and a conceptual framework to enhance patient care. J Am Coll Clin Pharm, 7(2) : 160-70.
Davis EA .2005 .Cipher of bad souls: an ethnography of madness and responsibility in Greek Thrace. , : .
Dragomani R.,Hill R. . .No child left behind: a quality improvement clinical implementation to improve the treatment outcomes, quality of care, and quality of life for school-aged children with attentiondeficit/hyperactivity disorder at a rural primary care practice [dissertation]. , : .
Hansen JM,Nørgaard JD,Sporrong SK .2022 .A systematic review of pharmacogenetic testing in primary care: attitudes of patients, general practitioners, and pharmacists. Res Soc Adm Pharm, 18(8) : 3230-8.
McDermott JH,Wright S,Sharma V,Newman WG,Payne K .2022 .Characterizing pharmacogenetic programs using the consolidated framework for implementation research: a structured scoping review. Front Med, 9 : 945352.
Kim JA,Ceccarelli R,Lu CY .2021 .Pharmacogenomic biomarkers in US FDA-approved drug labels (. J Pers Med, 11(3) : 179.
Kirchheiner J,Fuhr U,Brockmöller J .2005 .Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov. , 4(8) : 639-47.
Bostwick JM . .A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. InMayo Clinic Proceedings 2010 Jun, 85(6) : 538-550.
Simmons MB,Hetrick SE,Jorm AF .2013 .Making decisions about treatment for young people diagnosed with depressive disorders: a qualitative study of clinicians' experiences. BMC Psychiatry, 13 : 1-6.
Khan PA . .Personalized medicine: optimizing treatment with the right drug, for the right patient, and at the right dose through pharmacogenomics. Pristyn Research Solutions., : .
Fleming JM .2020 .Pharmacogenomics in primary care: barriers to implementation [DNP scholarly project]. Lynchburg, : .
Klein ME,Parvez MM,Shin JG. .2017 .Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci, 106(9) : 2368-79.
Clayton EW,Evans BJ,Hazel JW,Rothstein MA .2019 .The law of genetic privacy: applications, implications, and limitations. J Law Biosci, 6(1) : 1-36.
Moyer AM,Caraballo PJ .2017 .The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoecon Outcomes Res, 17(6) : 567-77.
Amare AT,Schubert KO,Baune BT .2017 .Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry. EPMA J, 8 : 211-27.
Xu L,Li L,Wang Q,Pan B,Zheng L,Lin Z .2024 .Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: a randomized clinical trial. J Affect Disord, 359 : 117-24.
Miller JJ,Fletcher K,Kabat-Zinn J .1995 .Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen Hosp Psychiatry, 17(3) : 192-200.
Tucker L. Pharmacogenomics . .: a primer for policymakers.. , : .
Ferwerda ME,Wright JA,El Melik RM,Swen JJ,Houwink EJ .2024 .Pharmacogenetic educational needs and the role of pharmacogenetics in primary care: a focus group study with multiple perspectives. Front Pharmacol, 15 : 1404370.
Carvalho . .Pharmacogenomics for psychiatry: focusing on drug metabolizing enzymes and transporters, with validated methodology for CYP2D6 and CYP2C19 Including for a Novel SubHaplotype [master's thesis]. , : .
Rantucci MJ .2007 .Lippincott Williams. , : .
McKittrick .2014 .A. A review of the current state of clinical pharmacogenomic testing: an examination of existing and potential roles for genetic counselors and pharmacists. , : .
Hess GP,Fonseca E,Scott R,Fagerness J .2015 .Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res, 97 : e13.
Roberts B,Cooper Z,Lu S,Stanley S,Majda BT,Collins KR .2023 .Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review. Front Pharmacol, 14 : 1267294.
Taherdoost H,Ghofrani A .2024 .AI and the evolution of personalized medicine in pharmacogenomics. Intell Pharm, : .